申请人:Hoffmann-La Roche Inc..
公开号:US06265446B1
公开(公告)日:2001-07-24
Hydrazine derivatives of the formula
wherein R1 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl, aryl or aryl-lower alkyl, R2 represents heterocyclyl or NR5R6, R3 represents hydrogen, lower alkyl, halo-lower alkyl, cyano-lower alkyl, hydroxy-lower alkyl, amino-lower alkyl, lower alkoxy-lower alkyl, lower alkoxycarbonyl-lower alkyl, lower cycloalkyl-lower alkyl, aryl-lower alkyl, heterocyclyl-lower alkyl, heterocyclylcarbonyl-lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, aryl, heteroaryl or aryl-lower alkyl, R4 represents lower alkyl, lower alkenyl, lower cycloalkyl, lower cycloalkyl-lower alkyl or a grouping of the formula -Z-aryl, -Z-heterocyclyl or —(CH2)n—, CH═CR7R8, R5 and R6 each independently represent hydrogen or lower alkyl, R7 and R8 each independently represent hydrogen or lower alkyl or R7 and R8 together represent lower alkylene in which one CH2 group is optionally replaced by a hetero atom, X and Z each represent a spacer group, and n stands for 0, 1 or 2, and their pharmaceutically acceptable salts thereof, inhibit the release of tumor necrosis factor alpha (TNF-&agr;) from cells. They can be used as medicaments, especially in the treatment of inflammatory and autoimmune diseases, osteoarthritis, respiratory diseases, tumors, cachexia, cardiovascular diseases, fever, haemorrhage and sepsis.
氢肼衍生物的化学式如下:
其中R1代表较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基、芳基或芳基-较低的烷基,R2代表杂环烷基或NR5R6,R3代表氢、较低的烷基、卤代-较低的烷基、氰基-较低的烷基、羟基-较低的烷基、氨基-较低的烷基、较低的烷氧基-较低的烷基、较低的烷氧羰基-较低的烷基、较低的环烷基-较低的烷基、芳基-较低的烷基、杂环烷基-较低的烷基、杂环烷基羰基-较低的烷基、较低的烯基、较低的炔基、较低的环烷基、芳基、杂芳基或芳基-较低的烷基,R4代表较低的烷基、较低的烯基、较低的环烷基、较低的环烷基-较低的烷基或化学式-Z-芳基、-Z-杂环烷基或—(CH2)n—、CH═CR7R8的基团,R5和R6各自独立地代表氢或较低的烷基,R7和R8各自独立地代表氢或较低的烷基,或者R7和R8一起代表较低的烷基,其中一个CH2基团可选择性地被一个杂原子取代,X和Z各自代表一个间隔基团,n代表0、1或2,以及它们的药学上可接受的盐,可以抑制细胞释放肿瘤坏死因子α(TNF-α)。它们可用作药物,特别是用于治疗炎症和自身免疫性疾病、骨关节炎、呼吸道疾病、肿瘤、消瘦症、心血管疾病、发热、出血和败血症。